Immune tolerance induction in severe haemophilia A: a UKHCDO inhibitor and paediatric working party consensus update.
Hart, Daniel P Alamelu, Jayanthi Bhatnagar, Neha Biss, Tina Collins, Peter W Hall, Georgina Hay, Charles Liesner, Ri Makris, Michael Mathias, Mary
Hart, Daniel P
Alamelu, Jayanthi
Bhatnagar, Neha
Biss, Tina
Collins, Peter W
Hall, Georgina
Hay, Charles
Liesner, Ri
Makris, Michael
Mathias, Mary
Abstract
Introduction: In good risk patients (historic inhibitor peak < 200BU), the International Immune Tolerance Study demonstrated equal efficacy to induce tolerance between high (200iu/kg/day) and low dose (50iu/kg ×3 times/week) immune tolerance induction (ITI) regimens. However, the trial stopped early on account of the excessive bleed rate in the low dose ITI arm.
Methods: United Kingdom Haemophilia Centre Doctors' Organization (UKHCDO) Paediatric and Inhibitor working parties considered available ITI data alongside the bi-phenotypic antibody emicizumab (Hemlibra®) efficacy and safety data to develop a consensus guideline for the future UK ITI guideline.
Results: This revision of UKHCDO ITI guidance incorporates the recommendation to use emicizumab as a prophylaxis haemostatic agent to reduce bleeding rates and to facilitate low dose and reduced frequency of FVIII CFC for ITI in the majority of children.
Conclusion: This consensus protocol will facilitate future evaluation of ITI outcomes in the evolving landscape of haemophilia therapeutics and ITI strategies.
MIDER Authors
Citations
Altmetric:
Date
2021-08-17
Type
Article
Subject
Paediatrics
Collections
Citation
Hart DP, Alamelu J, Bhatnagar N, Biss T, Collins PW, Hall G, Hay C, Liesner R, Makris M, Mathias M, Motwani J, Palmer B, Payne J, Percy C, Richards M, Riddell A, Talks K, Tunstall O, Chalmers E. Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update. Haemophilia. 2021 Nov;27(6):932-937. doi: 10.1111/hae.14381. Epub 2021 Aug 17
Journal / Source Title
Haemophilia
DOI
10.1111/hae.14381
PMID
34403546
Publisher
Wiley
Publisher’s URL
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2516